Rejected neurodegeneration drug partially rehabilitated
Latrepiridine, a promising drug for the treatment of Alzheimer's disease, rejected after the failure of a phase III clinical trial, was rehabilitated as a result of a study that revealed two mechanisms of its action.
16.08.2012